{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:40:30Z","timestamp":1792629630115,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s10147-025-02792-4","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T05:33:55Z","timestamp":1748496835000},"page":"1268-1275","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Multidisciplinary treatment for advanced gastric cancer"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8698-8923","authenticated-orcid":false,"given":"Shingo","family":"Kanaji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Urakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasufumi","family":"Koterazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichiro","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Otowa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimihiro","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeru","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Kakeji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"key":"2792_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87\u2013108","journal-title":"CA Cancer J Clin"},{"key":"2792_CR2","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1200\/JCO.2011.36.5908","volume":"29","author":"M Sasako","year":"2011","unstructured":"Sasako M, Sakuramoto S, Katai H et al (2011) Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29:4387\u20134393","journal-title":"J Clin Oncol"},{"key":"2792_CR3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0140-6736(11)61873-4","volume":"379","author":"YJ Bang","year":"2012","unstructured":"Bang YJ, Kim YW, Yang HK et al (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (classic): a phase 3 open-label, randomised controlled trial. Lancet 379:315\u2013321. https:\/\/doi.org\/10.1016\/S0140-6736(11)61873-4. ([EPub] PMID: 22226517)","journal-title":"Lancet"},{"key":"2792_CR4","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1200\/JCO.18.01138","volume":"37","author":"K Yoshida","year":"2019","unstructured":"Yoshida K, Kodera Y, Kochi M et al (2019) Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: Interim analysis of jaccro GC-07, a randomized controlled trial. J Clin Oncol 37:1296\u20131304. https:\/\/doi.org\/10.1200\/JCO.18.01138. ([EPub].PMID:30925125,PMCID:PMC6524985)","journal-title":"J Clin Oncol"},{"key":"2792_CR5","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(14)70473-5","volume":"15","author":"SH Noh","year":"2014","unstructured":"Noh SH, Park SR, Yang HK et al (2014) Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (classic): 5-year follow-up of an openlabel, randomised phase 3 trial. Lancet Oncol 15:1389\u20131396","journal-title":"Lancet Oncol"},{"key":"2792_CR6","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa010187","volume":"345","author":"JS Macdonald","year":"2001","unstructured":"Macdonald JS, Smalley SR, Benedetti J et al (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725\u2013730","journal-title":"N Engl J Med"},{"key":"2792_CR7","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1200\/JCO.2011.36.7136","volume":"30","author":"SR Smalley","year":"2012","unstructured":"Smalley SR, Benedetti JK, Haller DG et al (2012) Updated analysis of SWOG-directed Intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 30:2327\u20132333","journal-title":"J Clin Oncol"},{"key":"2792_CR8","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1200\/JCO.2009.26.9654","volume":"28","author":"JL Dikken","year":"2010","unstructured":"Dikken JL, Jansen EP, Cats A et al (2010) Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol 28:2430\u20132436","journal-title":"J Clin Oncol"},{"key":"2792_CR9","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1200\/JCO.2011.39.1953","volume":"30","author":"J Lee","year":"2012","unstructured":"Lee J, Lim DH, Kim S et al (2012) Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 30:268\u2013273","journal-title":"J Clin Oncol"},{"key":"2792_CR10","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.annonc.2020.11.017","volume":"32","author":"SH Park","year":"2021","unstructured":"Park SH, Lim DH, Sohn TS et al (2021) A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial. Ann Oncol 32:368\u2013374. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.017. ([EPub] 2020 Dec 3. PMID: 33278599)","journal-title":"Ann Oncol"},{"key":"2792_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11\u201320","journal-title":"N Engl J Med"},{"key":"2792_CR12","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"S-E Al-Batran","year":"2019","unstructured":"Al-Batran S-E, Homann N, Pauligk C et al (2019) Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet 393:1948\u20131957","journal-title":"Lancet"},{"key":"2792_CR13","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/S1470-2045(16)30531-9","volume":"17","author":"SE Al-Batran","year":"2016","unstructured":"Al-Batran SE, Hofheinz RD, Pauligk C et al (2016) Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2\/3 trial. Lancet Oncol 17:1697\u20131708","journal-title":"Lancet Oncol"},{"key":"2792_CR14","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/bjs.9484","volume":"101","author":"A Tsuburaya","year":"2014","unstructured":"Tsuburaya A, Mizusawa J, Tanaka Y et al (2014) Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg 101:653\u2013660","journal-title":"Br J Surg"},{"key":"2792_CR15","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s10120-023-01453-7","volume":"27","author":"Y Kurokawa","year":"2024","unstructured":"Kurokawa Y, Doki Y, Kitabayashi R et al (2024) Short-term outcomes of preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis (JCOG1704). Gastric Cancer 27:366\u2013374. https:\/\/doi.org\/10.1007\/s10120-023-01453-7. ([EPub]. PMID: 38180622, PMCID: PMC10896774)","journal-title":"Gastric Cancer"},{"key":"2792_CR16","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1200\/JCO.20.02914","volume":"39","author":"YK Kang","year":"2021","unstructured":"Kang YK, Yook JH, Park YK et al (2021) Prodigy: a phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer. J Clin Oncol 39:2903\u20132913. https:\/\/doi.org\/10.1200\/JCO.20.02914. ([EPub]. PMID: 34133211, PMCID: PMC8425847)","journal-title":"J Clin Oncol"},{"key":"2792_CR17","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1200\/JCO.23.02167","volume":"42","author":"YK Kang","year":"2024","unstructured":"Kang YK, Kim HD, Yook JH et al (2024) Neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 for resectable advanced gastric cancer: updated overall survival outcomes from phase III PRODIGY. J Clin Oncol 42:2961\u20132965. https:\/\/doi.org\/10.1200\/JCO.23.02167. ([EPub] PMID: 38996201)","journal-title":"J Clin Oncol"},{"key":"2792_CR18","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s10120-014-0398-3","volume":"18","author":"T Matsumoto","year":"2015","unstructured":"Matsumoto T, Sasako M, Mizusawa J et al (2015) HER2 expression in locally advanced gastric cancer with extensive lymph node (bulky N2 or paraaortic) metastasis (JCOG1005-A trial). Gastric Cancer 18:467\u2013475. https:\/\/doi.org\/10.1007\/s10120-014-0398-3. ([EPub] 2014 Jul 4. PMID: 24993498)","journal-title":"Gastric Cancer"},{"key":"2792_CR19","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1093\/jjco\/hyv134","volume":"45","author":"K Kataoka","year":"2015","unstructured":"Kataoka K, Tokunaga M, Mizusawa J et al (2015) A randomized phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan clinical oncology group study JCOG1301 (trigger study). Jpn J Clin Oncol 45:1082\u20131086. https:\/\/doi.org\/10.1093\/jjco\/hyv134. ([EPub] PMID: 26355164)","journal-title":"Jpn J Clin Oncol"},{"key":"2792_CR20","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1007\/s10120-024-01467-9","volume":"27","author":"M Tokunaga","year":"2024","unstructured":"Tokunaga M, Machida N, Mizusawa J et al (2024) Early endpoints of a randomized phase II trial of preoperative chemotherapy with S-1\/CDDP with or without trastuzumab followed by surgery for HER2-positive resectable gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301C (Trigger Study). Gastric Cancer 27:580\u2013589. https:\/\/doi.org\/10.1007\/s10120-024-01467-9. ([EPub] PMID: 38243037)","journal-title":"Gastric Cancer"},{"key":"2792_CR21","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ejca.2020.12.005","volume":"145","author":"F Rivera","year":"2021","unstructured":"Rivera F, Izquierdo-Manuel M, Garc\u00eda-Alfonso P et al (2021) Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial. Eur J Cancer 145:158\u2013167. https:\/\/doi.org\/10.1016\/j.ejca.2020.12.005. ([EPub] PMID: 33485079)","journal-title":"Eur J Cancer"},{"key":"2792_CR22","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1002\/ijc.33696","volume":"149","author":"RD Hofheinz","year":"2021","unstructured":"Hofheinz RD, Hegewisch-Becker S, Kunzmann V et al (2021) Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: a phase II trial of the arbeitsgemeinschaft internistische onkologie gastric cancer study group. Int J Cancer 149:1322\u20131331. https:\/\/doi.org\/10.1002\/ijc.33696. ([EPub] PMID: 34019698)","journal-title":"Int J Cancer"},{"key":"2792_CR23","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1200\/JCO.22.00380","volume":"40","author":"RD Hofheinz","year":"2022","unstructured":"Hofheinz RD, Merx K, Haag GM et al (2022) FLOT versus FLOT\/trastuzumab\/pertuzumab perioperative therapy of human epidermal growth factor receptor 2-positive resectable esophagogastric adenocarcinoma: a randomized phase ii trial of the AIO EGA study group. J Clin Oncol 40:3750\u20133761. https:\/\/doi.org\/10.1200\/JCO.22.00380. ([EPub] PMID: 35709415)","journal-title":"J Clin Oncol"},{"key":"2792_CR24","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s10120-020-01136-7","volume":"24","author":"Y Iwasaki","year":"2021","unstructured":"Iwasaki Y, Terashima M, Mizusawa J et al (2021) Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial. Gastric Cancer 24:492\u2013502. https:\/\/doi.org\/10.1007\/s10120-020-01136-7. ([EPub] 2020 Nov 16. PMID: 33200303)","journal-title":"Gastric Cancer"},{"key":"2792_CR25","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.2217\/fon-2023-0605","volume":"19","author":"T Hashimoto","year":"2023","unstructured":"Hashimoto T, Nakayama I, Ohashi M et al (2023) Randomized phase II study comparing neoadjuvant 5-fluorouracil\/oxaliplatin\/docetaxel versus docetaxel\/oxaliplatin\/S-1 for patients with type 4 or large type 3 gastric cancer. Future Oncol 19:2147\u20132155. https:\/\/doi.org\/10.2217\/fon-2023-0605. ([EPub] PMID: 37882373)","journal-title":"Future Oncol"},{"key":"2792_CR26","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(21)00297-7","volume":"22","author":"X Zhang","year":"2021","unstructured":"Zhang X, Liang H, Li Z et al (2021) Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol 22:1081\u20131092","journal-title":"Lancet Oncol"},{"key":"2792_CR27","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1200\/JCO.2020.38.4_suppl.280","volume":"38","author":"X Wang","year":"2020","unstructured":"Wang X, Li S, Xie T et al (2020) Early results of the randomized, multicenter, controlled evaluation of S-1 and oxaliplatin as neoadjuvant chemotherapy for Chinese advanced gastric cancer patients (RESONANCE Trial). J Clin Oncol 38:280","journal-title":"J Clin Oncol"},{"key":"2792_CR28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12885-020-07764-7","volume":"21","author":"X Wang","year":"2021","unstructured":"Wang X, Li S, Sun Y et al (2021) The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial. BMC Cancer 21:20","journal-title":"BMC Cancer"},{"key":"2792_CR29","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/jjco\/hyad149","volume":"54","author":"R Kita","year":"2024","unstructured":"Kita R, Yanagimoto Y, Imazeki H et al (2024) Protocol digest of a randomized controlled adaptive phase II\/III trial of neoadjuvant chemotherapy for Japanese patients with oesophagogastric junction adenocarcinoma: Japan clinical oncology group study JCOG2203 (NEO-JPEG). Jpn J Clin Oncol 54:206\u2013211. https:\/\/doi.org\/10.1093\/jjco\/hyad149. (PMID: 37952093)","journal-title":"Jpn J Clin Oncol"},{"key":"2792_CR30","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","volume":"25","author":"K Shitara","year":"2024","unstructured":"Shitara K, Rha SY, Wyrwicz LS et al (2024) Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastrooesophageal cancer (KEYNOTE-585): An interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol 25:212\u2013224. https:\/\/doi.org\/10.1016\/S1470-2045(23)00541-7. ([EPub] 2023 Dec 19. PMID: 38134948)","journal-title":"Lancet Oncol"},{"key":"2792_CR31","doi-asserted-by":"publisher","first-page":"LBA246","DOI":"10.1200\/JCO.2024.42.3_suppl.LBA246","volume":"42","author":"YY Janjigian","year":"2024","unstructured":"Janjigian YY, Al-Batran SE, Wainberg ZA et al (2024) Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC\/GEJC): Subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study 2024 ASCO Annual Meeting. J Clin Oncol 42:LBA246\u2013LBA246. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_suppl.LBA246","journal-title":"J Clin Oncol"},{"key":"2792_CR32","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C et al (2019) Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet 393:1948\u20131957","journal-title":"Lancet"},{"key":"2792_CR33","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1200\/JCO.24.00795","volume":"43","author":"C Li","year":"2025","unstructured":"Li C, Tian Y, Zheng Y et al (2025) Pathologic response of phase III study: Perioperative camrelizumab plus rivoceranib and chemotherapy versus chemotherapy for locally advanced gastric cancer (DRAGON IV\/CAP 05). J Clin Oncol 43:464\u2013474. https:\/\/doi.org\/10.1200\/JCO.24.00795. ([EPub] 2024Oct9. PMID: 39383487, PMCID: PMC11776878)","journal-title":"J Clin Oncol"},{"key":"2792_CR34","doi-asserted-by":"crossref","unstructured":"Li C, Zheng Y, Shi Z, et al (2023) Perioperative camrelizumab I combined with rivoceranib I and chemotherapy (chemo) versus chemo for locally advanced resectable gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma: The first interim analysis of a randomized, phase III trial (Dragon IV). ESMO Congress, Madrid, Spain","DOI":"10.1016\/j.annonc.2023.09.1425"},{"key":"2792_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-022-01331-8","volume":"26","author":"Japanese Gastric Cancer Association","year":"2023","unstructured":"Japanese Gastric Cancer Association (2023) Japanese gastric cancer treatment guidelines 2021. Gastric Cancer. 26:1\u201325. https:\/\/doi.org\/10.1007\/s10120-022-01331-8. ([EPub] 2022 Nov 7. PMID: 36342574, PMCID: PMC9813208)","journal-title":"Gastric Cancer."},{"key":"2792_CR36","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jamaoncol.2017.0515","volume":"3","author":"SE Al-Batran","year":"2017","unstructured":"Al-Batran SE, Homann N, Pauligk C et al (2017) Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial. JAMA Oncol 3:1237\u20131244. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0515. (PMID:28448662,PMCID:PMC5824287)","journal-title":"JAMA Oncol"},{"key":"2792_CR37","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1186\/s12885-017-3918-9","volume":"17","author":"SE Al-Batran","year":"2017","unstructured":"Al-Batran SE, Goetze TO, Mueller DW et al (2017) The renaissance (AIO-FLOT5) trial: Effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO\/CAO-V\/CAOGI. BMC Cancer 17:893. https:\/\/doi.org\/10.1186\/s12885-017-3918-9","journal-title":"BMC Cancer"},{"key":"2792_CR38","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ags3.12515","volume":"6","author":"K Yoshida","year":"2022","unstructured":"Yoshida K, Yasufuku I, Terashima M et al (2022) International retrospective cohort study of conversion therapy for stage iv gastric cancer 1 (CONVO-GC-1). Ann Gastroenterol Surg 6:227\u2013240. https:\/\/doi.org\/10.1002\/ags3.12515. (PMID:35261948,PMCID:PMC8889854)","journal-title":"Ann Gastroenterol Surg"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02792-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02792-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02792-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T09:46:16Z","timestamp":1750758376000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02792-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2792"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02792-4","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"assertion":[{"value":"7 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We certify that this article presents no actual or potential conflict of interest. All authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}